Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Valneva SE - American Depositary Shares (NQ:VALN)

6.300 -0.110 (-1.72%)
Streaming Delayed Price Updated: 3:08 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Valneva SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events
FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including deaths, trigger a new safety assessment. 
Via Benzinga
Topics Death
Exposures Death Product Safety
Earnings Scheduled For May 7, 2025
Via Benzinga
Insights Ahead: Valneva's Quarterly Earnings
Via Benzinga
12 Analysts Assess Valneva: What You Need To Know
Via Benzinga
Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine
Valneva's chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and endemic regions. 
Via Benzinga
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday
Via Benzinga
4 Analysts Have This To Say About Valneva
Via Benzinga
Expert Ratings For Valneva
Via Benzinga
Breaking Down Valneva: 6 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For March 20, 2025
Via Benzinga
In-Depth Examination Of 6 Analyst Recommendations For Valneva
Via Benzinga
The Analyst Landscape: 6 Takes On Valneva
Via Benzinga
Analyst Scoreboard: 8 Ratings For Valneva
Via Benzinga
What Analysts Are Saying About Valneva Stock
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot
Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions. 
Via Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts. 
Via Benzinga
The Analyst Landscape: 6 Takes On Valneva
Via Benzinga
What Analysts Are Saying About Valneva Stock
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Exposures Product Safety
Palo Alto Networks To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study
Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion... 
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q2 2024
VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price. 
Via InvestorPlace
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025... 
Via Benzinga
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.